Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.

Antonia BringsMarie-Louise LehmannKathrin I FoersterJürgen BurhenneJohanna Weiss Walter Emil Haefeli David Czock

Published in: British journal of clinical pharmacology (2019)

Patients treated with rivaroxaban in combination with single modulators of multiple elimination pathways or multiple modulators of single elimination pathways (CYP3A, P-gp) require particular care.

Keyphrases

venous thromboembolism
small molecule
atrial fibrillation
pulmonary embolism
healthcare
palliative care
candida albicans
quality improvement
pain management
chronic pain
health insurance